IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.3013
+0.0153 (5.35%)
At close: May 1, 2026, 4:00 PM EDT
0.2911
-0.0102 (-3.39%)
After-hours: May 1, 2026, 4:20 PM EDT
IceCure Medical Revenue
In the year 2025, IceCure Medical had annual revenue of $3.38M with 2.67% growth. IceCure Medical had revenue of $1.28M in the quarter ending December 31, 2025, with 46.17% growth.
Revenue (ttm)
$3.38M
Revenue Growth
+2.67%
P/S Ratio
7.21
Revenue / Employee
$48,971
Employees
69
Market Cap
24.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.38M | 88.00K | 2.67% |
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nortech Systems | 118.37M |
| TELA Bio | 80.28M |
| IRIDEX | 52.68M |
| Myomo | 40.93M |
| Lifeward | 22.03M |
| Pulsenmore | 12.55M |
| Picard Medical | 4.94M |
| VolitionRx | 1.73M |
ICCM News
- 10 days ago - IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025 - PRNewsWire
- 5 weeks ago - IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement - PRNewsWire
- 5 weeks ago - IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates - PRNewsWire
- 5 weeks ago - IceCure Appoints Meir Peleg as Chief Financial Officer - PRNewsWire
- 6 weeks ago - IceCure Medical Earnings Call Transcript: Q4 2025 - Transcripts
- 6 weeks ago - IceCure Reports 2025 Full Year Financial & Operational Results - PRNewsWire
- 7 weeks ago - U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer - PRNewsWire
- 7 weeks ago - IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026 - PRNewsWire